Asia FX weakens slightly, rupee recovers from record low as RBI holds rates
Investing.com - Evercore ISI reduced its price target on Twist Bioscience (NASDAQ:TWST) to $46.00 from $50.00 while maintaining an Outperform rating on the stock. The company, currently trading at $29.65, has seen its shares decline 7.8% in the past week, according to InvestingPro data.
The adjustment follows what the research firm described as a "decent print" for Twist Bioscience, with particularly strong performance in the next-generation sequencing (NGS) segment and solid gross margin results.
Evercore noted that approximately $5 million in revenue is being pushed out as one of Twist’s top 10 customers transitions to a commercial setting, creating some revenue timing shifts between quarters.
The revenue pushout will affect the company’s fourth quarter results with lower NGS revenues quarter-over-quarter, with some impact expected to linger into the first quarter of fiscal year 2026.
Despite these short-term challenges, Evercore maintained its Outperform rating, suggesting the 15% share price decline following the news appeared "egregious" and created a buying opportunity for investors.
In other recent news, Twist Bioscience Corp reported its Q3 2025 earnings, highlighting an 18% year-over-year increase in revenue, reaching $96.1 million. Despite the revenue growth, the company posted an adjusted EBITDA loss of $8 million, which marked an improvement from the previous fiscal year. Analysts have noted this performance as a significant development in the company’s financial trajectory. The revenue increase and improved EBITDA loss are seen as critical indicators of the company’s operational progress. Investors are closely monitoring these financial results to assess the company’s future potential. Additionally, there have been no recent mergers or acquisitions reported by Twist Bioscience. Analyst firms have yet to provide any upgrades or downgrades following these earnings results. These recent developments are shaping the current investment landscape for Twist Bioscience.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.